BRPI0412577A - derivados de aminoquinolina e seu uso como ligantes de adenosina a3 - Google Patents

derivados de aminoquinolina e seu uso como ligantes de adenosina a3

Info

Publication number
BRPI0412577A
BRPI0412577A BRPI0412577-0A BRPI0412577A BRPI0412577A BR PI0412577 A BRPI0412577 A BR PI0412577A BR PI0412577 A BRPI0412577 A BR PI0412577A BR PI0412577 A BRPI0412577 A BR PI0412577A
Authority
BR
Brazil
Prior art keywords
adenosine
binders
aminoquinoline derivatives
derivatives
solvates
Prior art date
Application number
BRPI0412577-0A
Other languages
English (en)
Inventor
Peter Aranyi
Sandor Batori
Geza Timari
Kinga Boer
Zoltan Kapui
Endre Mikus
Katalin Urban-Szabo
Katalin Gerber
Judit Vargane Szeredi
Michel Finet
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0302440A external-priority patent/HUP0302440A3/hu
Priority claimed from HU0401468A external-priority patent/HUP0401468A3/hu
Priority claimed from HU0401467A external-priority patent/HUP0401467A3/hu
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0412577A publication Critical patent/BRPI0412577A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

"DERIVADOS DE AMINOQUINOLINA E SEU USO COMO LIGANTES DE ADENOSINA A3". A presente invenção refere-se a compostos de fórmula geral (I) e seus sais, solvatos, isómeros (tautómeros, desmotropos, isómeros oticamente ativos), assim como seus sais e solvatos, são fortes ligantes do receptor A~ 3~ de adenosina, de preferência antagonistas.
BRPI0412577-0A 2003-07-31 2004-07-23 derivados de aminoquinolina e seu uso como ligantes de adenosina a3 BRPI0412577A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
HU0302440A HUP0302440A3 (en) 2003-07-31 2003-07-31 Aminoquinoline derivatives, process for producing them and pharmaceutical compositions containing them
HU0401468A HUP0401468A3 (en) 2004-07-21 2004-07-21 Aminoquinoline derivatives and process for producing them
HU0401467A HUP0401467A3 (en) 2004-07-21 2004-07-21 Aminoquinoline derivatives, process for producing them and their use as adenosine a3 ligands
PCT/HU2004/000080 WO2005009969A1 (en) 2003-07-31 2004-07-23 Aminoquinoline derivatives and their use as adenosine a3 ligands

Publications (1)

Publication Number Publication Date
BRPI0412577A true BRPI0412577A (pt) 2006-09-19

Family

ID=90001697

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412577-0A BRPI0412577A (pt) 2003-07-31 2004-07-23 derivados de aminoquinolina e seu uso como ligantes de adenosina a3

Country Status (24)

Country Link
US (4) US7547696B2 (pt)
EP (1) EP1663982B1 (pt)
JP (1) JP2007500689A (pt)
KR (1) KR20060065662A (pt)
AR (1) AR045326A1 (pt)
AU (1) AU2004259127B2 (pt)
BR (1) BRPI0412577A (pt)
CA (1) CA2534105C (pt)
CY (1) CY1107875T1 (pt)
DE (1) DE602004010284T2 (pt)
DK (1) DK1663982T3 (pt)
ES (1) ES2295923T3 (pt)
HR (1) HRP20070584T3 (pt)
IL (1) IL173416A (pt)
MA (1) MA27991A1 (pt)
ME (1) MEP19108A (pt)
MX (1) MXPA06001254A (pt)
NO (1) NO20060702L (pt)
NZ (1) NZ545580A (pt)
PL (1) PL1663982T3 (pt)
PT (1) PT1663982E (pt)
RS (1) RS20060072A (pt)
TW (1) TW200510320A (pt)
WO (1) WO2005009969A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400812A2 (en) * 2004-04-19 2006-02-28 Sanofi Aventis Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
WO2006010142A2 (en) 2004-07-14 2006-01-26 Ligand Pharmaceuticals, Inc. Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use
WO2006023158A2 (en) 2004-07-14 2006-03-02 Ligand Pharmaceuticals, Inc. Mineralocorticoid receptor modulator compounds and methods, and pharmaceutical compositions containing these compounds
EP1893604B1 (de) * 2005-06-01 2009-02-11 Clariant Produkte (Deutschland) GmbH Verfahren zur herstellung von n,n-bis(pyridin-2-yl-methyl)-1,1-bis(pyridin-2-yl)-1-aminoalkan-verbindungen und diese verbindungen enthaltende metallkomplex-salze
WO2007002781A2 (en) * 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells
ES2361886T3 (es) * 2006-06-27 2011-06-24 Cbt Development Limited Profármacos adenosina acetil 2',3'-metilideno novedosos para uso como profármacos para agonistas del receptor adenosina.
ES2380135T3 (es) * 2006-11-22 2012-05-08 Ajinomoto Co., Inc. Método de preparación de derivados de fenilalanina que tienen esqueleto de quinazolinadiona e intermedios para su preparación
HUP0700395A2 (en) * 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
JP2012051803A (ja) * 2008-12-25 2012-03-15 Kyorin Pharmaceutical Co Ltd 環状アミノ安息香酸エステル誘導体の製造方法
EP2504315A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011063272A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
US8735384B2 (en) 2010-01-19 2014-05-27 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
TW201718536A (zh) * 2015-08-03 2017-06-01 必治妥美雅史谷比公司 可作為ＴＮＦα調節劑之雜環化合物
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
WO2000061556A1 (en) 1999-04-09 2000-10-19 Meiji Seika Kaisha, Ltd. Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
WO2002096879A1 (en) * 2001-05-31 2002-12-05 Sanofi-Synthelabo Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands

Also Published As

Publication number Publication date
AU2004259127B2 (en) 2009-05-28
US7547696B2 (en) 2009-06-16
MXPA06001254A (es) 2006-05-17
US7799922B2 (en) 2010-09-21
RS20060072A (sr) 2008-08-07
DE602004010284D1 (de) 2008-01-03
KR20060065662A (ko) 2006-06-14
EP1663982B1 (en) 2007-11-21
US8071601B2 (en) 2011-12-06
NO20060702L (no) 2006-02-28
ES2295923T3 (es) 2008-04-16
AU2004259127A1 (en) 2005-02-03
PT1663982E (pt) 2008-01-31
CA2534105C (en) 2012-02-21
IL173416A0 (en) 2006-06-11
JP2007500689A (ja) 2007-01-18
IL173416A (en) 2011-03-31
CY1107875T1 (el) 2013-06-19
US20060211689A1 (en) 2006-09-21
US20110009626A1 (en) 2011-01-13
CA2534105A1 (en) 2005-02-03
US20090247745A1 (en) 2009-10-01
WO2005009969A1 (en) 2005-02-03
TW200510320A (en) 2005-03-16
PL1663982T3 (pl) 2008-03-31
HRP20070584T3 (hr) 2008-01-31
NZ545580A (en) 2009-03-31
EP1663982A1 (en) 2006-06-07
MA27991A1 (fr) 2006-07-03
AR045326A1 (es) 2005-10-26
DE602004010284T2 (de) 2008-10-02
HK1088261A1 (en) 2006-11-03
US20110112092A1 (en) 2011-05-12
MEP19108A (en) 2010-06-10
DK1663982T3 (da) 2008-03-17

Similar Documents

Publication Publication Date Title
ATE524466T1 (de) 3-azabicycloä3.3.0üoktanverbindungen
BRPI0417478A (pt) 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina
BRPI0414570A (pt) derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso
UY28623A1 (es) Derivados de pirazol y usos de los mismos
ATE271039T1 (de) Harnstoffderivate wirksam als muscarinrezeptor- antagonisten
ATE483707T1 (de) 2-cyclopropylthiazolderivate
BRPI0412695A (pt) derivados de quinolina e quinazolina dotados de afinidade para receptores do tipo 5ht1
BR0014279A (pt) Derivados de piperazina como antagonistas 5-ht1b
ECSP034640A (es) Derivados de feniletenilo o feniletinilo como antagonistas del receptor del glutamato
BR0211805A (pt) Herbicidas
ATE286897T1 (de) Morpholinderivate als antagonisten an orexinrezeptoren
DE60228487D1 (de) Ethylenediaminderivate und ihre verwendung als orexinrezeptorantagonisten
ATE324371T1 (de) N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten
BRPI0518607A2 (pt) derivados de pirrol tendo atividade antagonista de receptor crth2
TR200101155T2 (tr) 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III
GT200900026A (es) Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
BRPI0409002A (pt) pirazóis 1,3,4-substituìdos para uso como antagonistas receptores 5h-t no tratamento de psicoses e distúrbios neurológicos
TW200606152A (en) Piperidine compound and process for preparing the same
MEP19108A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
BRPI0406704A (pt) Antagonistas de 5ht~7~ e agonistas inversos
ECSP066474A (es) Arilindenopiridinas y arilindenopirimidinas y su uso como antagonista del receptor adenosina a2a
EP1430898A4 (en) Receptor antagonist
CR9058A (es) Derivados de indol como inhibidores de la adenilato ciclasa soluble
BRPI0516381A (pt) derivados de cromano e seu uso como ligandos de receptor de 5-ht
PT1497292E (pt) Derivados de azaindolilpiperidina como agentes anti-histaminicos e antialergicos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.